11:00 AM EDT, 07/29/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Monday it signed a co-promotion agreement for the Zoryve products with Kowa Pharmaceuticals America.

Financial terms weren't disclosed.

Kowa will market and promote the Zoryve cream and foam to primary care practitioners and pediatricians for all US Food and Drug Administration-approved indications, while Arcutis will have the responsibility for the marketing and sales to dermatologists, other dermatology clinicians and related specialists.

Arcutis said it will recognize all revenue and will have sole responsibility for producing Zoryve during the partnership's five-year term.

The company's shares were down 6% in recent trading.

Price: 9.44, Change: -0.63, Percent Change: -6.26